ReviewExploration (Beijing, China)2023
Tracking tumor heterogeneity and progression with near-infrared II fluorophores.
Review in Exploration (Beijing, China), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Application-Driven Modular Design of Gold Nanoclusters for In Vivo Fluorescence Imaging.Small methods · 2026Review
- Liquid Metal Materials for Tumor Diagnosis and Treatment.Advanced healthcare materials · 2026Review
- Concurrent Evaluation of Liver and Kidney Function by NIR-IIChemical & biomedical imaging · 2026Article
- Integrated theranostic nanoplatform empowers precision cancer care via radionuclide-labeled NIR-II aggregation-induced emission luminogens.Nature communications · 2026Article
- D-π-A sensitized carbon dots as long-lived type-I/Ⅱ photosensitizers for NIR-excited hypoxia-regulated photodynamic therapy.Nature communications · 2026Article
- Two-dimensional NIR-II AIE nanotheranostic probes with ultralarge Stokes shifts for surgical navigation and ablation of glioma.Science advances · 2026Article
- Rationally designed thiazole-based COF with multiphoton activity for drug delivery and synergistic therapy of deep-seated tumors.Journal of nanobiotechnology · 2026Article
- NIR-II fluorescence imaging with ICG improves intraoperative visualization of pelvic autonomic nerves.Clinical and translational medicine · 2026Article
- A novel near-infrared II viscosity-responsive probe for surgical fluorescence guidance: laboratory investigation in a murine subcutaneous glioma model.Frontiers in oncology · 2026Article
- Advances in NIR-II Fluorescence Laparoscopy for Precision Diagnosis and Theranostics of Urological Oncology.International journal of nanomedicine · 2026Review
- Engineered nanoparticles potentials in male reproduction.Andrology · 2025Review
- Molecular Targets and Nano-Technological Approaches in the Treatment of Hepatic Carcinoma.Current cancer drug targets · 2025Review
- Comprehensive pan-cancer analysis identifies PLAG1 as a key regulator of tumor immune microenvironment and prognostic biomarker.Frontiers in immunology · 2025Article
- A FRET-based off-on AIE nanoprobe enables instant and stain-free detection of hypoxic niches in tumor sections.Theranostics · 2025Article
- Janus-Structured Micro/Nanomotors: Self-Propelled Mechanisms and Biomedical Applications.Biomaterials research · 2025Review
- Structural characterization of a polysaccharide from Qi-Gui herb pair and its anti-tumor activity in colon cancer cells.Frontiers in pharmacology · 2025Article
- Diagnostic and Therapeutic Advances of RNAs in Precision Medicine of Gastrointestinal Tumors.Biomedicines · 2024Review
- Dynamic Acoustic Holography: One-Shot High-Precision and High-Information Methodology.Micromachines · 2024Article
- Engineering Tumor-Specific Nanotheranostic Agent with MR Image-Guided NIR-II & -III Photodynamic Therapy to Combat Against Deeply Seated Orthotopic Glioblastoma.Small science · 2024Article
- The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways.Cell communication and signaling : CCS · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Heterogeneous cells are the main feature of tumors with unique genetic and phenotypic characteristics, which can stimulate differentially the progression, metastasis, and drug resistance. Importantly, heterogeneity is pervasive in human malignant tumors, and identification of the degree of tumor heterogeneity in individual tumors and progression is a critical task for tumor treatment. However, current medical tests cannot meet these needs; in particular, the need for noninvasive visualization of single-cell heterogeneity. Near-infrared II (NIR-II, 1000-1700 nm) imaging exhibits an exciting prospect for non-invasive monitoring due to the high temporal-spatial resolution. More importantly, NIR-II imaging displays more extended tissue penetration depths and reduced tissue backgrounds because of the significantly lower photon scattering and tissue autofluorescence than traditional the near-infrared I (NIR-I) imaging. In this review, we summarize systematically the advances made in NIR-II in tumor imaging, especially in the detection of tumor heterogeneity and progression as well as in tumor treatment. As a non-invasive visual inspection modality, NIR-II imaging shows promising prospects for understanding the differences in tumor heterogeneity and progression and is envisioned to have the potential to be used clinically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.